利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.017 秒)

    Glucagon receptors
    5.
    发明公开
    Glucagon receptors 失效
    Glucagonrezeptoren

    公开(公告)号：EP1514932A2

    公开(公告)日：2005-03-16

    申请号：EP04026892.2

    申请日：1993-08-30

    申请人： NOVO NORDISK A/S

    发明人： Kindsvogle, Wayne R. ,  Sheppard, Paul O. ,  Grant, Francis J. ,  Lok, Si ,  Jelinek, Laura J. ,  Kuijper, Joseph L. ,  Foster, Donald C. ,  O'Hara, Patrick J.

    IPC分类号： C12N15/12 ,  C12N15/62 ,  C12N5/10 ,  C07K14/72 ,  C07K16/28 ,  C12N15/06 ,  C12Q1/68 ,  C12Q1/66 ,  G01N33/74

    CPC分类号： C07K14/72 ,  C07K2319/00 ,  C07K2319/02 ,  C12Q1/66 ,  G01N33/74 ,  G01N2333/605 ,  G01N2333/72

    摘要： The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs. The present invention also provides a method for detecting the presence of glucagon antagonists, comprising the steps (a) exposing a compound in the presence of a glucagon agonist to a recombinant glucagon receptor coupled to a response pathway under conditions and for time sufficient to allow binding of the compound to the receptor and an associated response through the pathway, and (b) detecting a reduction to the stimulation of the response pathway resulting from the binding of the compound to the glucagon receptor, relative to the stimulation of the response pathway by the glucagon agonist alone and therefrom determining the presence of a glucagon antagonist.

    摘要翻译： 本发明提供了分离的DNA分子，其包含编码胰高血糖素受体的DNA区段。 还提供了DNA构建体，其包含编码与第一DNA区段表达所需的另外的DNA区段可操作地连接的胰高血糖素受体的第一DNA区段，以及含有该DNA构建体的宿主细胞。 本发明还提供了一种用于检测胰高血糖素拮抗剂的存在的方法，其包括以下步骤：（a）将在胰高血糖素激动剂存在下的化合物暴露于在足以允许结合的条件和时间的情况下，与重要的胰高血糖素受体偶联至应答途径 的化合物与受体的相关应答和通过该途径的相关应答，和（b）相对于由该化合物与胰高血糖素受体结合的刺激反应路径的刺激， 胰高血糖素激动剂单独和由此决定胰高血糖素拮抗剂的存在。

    Fibrinolytic proteins
    6.
    发明公开
    Fibrinolytic proteins 失效
    纤维蛋白酶蛋白

    公开(公告)号：EP0292009A1

    公开(公告)日：1988-11-23

    申请号：EP88108148.3

    申请日：1988-05-20

    申请人： ZYMOGENETICS, INC.

    发明人： Mulvihill, Eileen R. ,  Kumar, Anur Ashok ,  Foster, Donald C. ,  Rao, Donald D. ,  O'Hara, Patrick J. ,  Insley, Margaret Y.

    IPC分类号： C12N9/50 ,  C12N15/00 ,  C07H21/04 ,  A61K37/54 ,  C12N5/00

    CPC分类号： C12N9/6459 ,  A61K38/00 ,  C12Y304/21069

    摘要： Tissue-type plasminogen activator (t-PA) homologs having the fibrinolytic capacity of native t-PA in the presence of fibrin are disclosed. These homologs consist essentially of an amino-terminal fibrin-binding domain and a carboxyl-terminal serine protease domain, wherein said homolog is essentially fibrin-binding inactive in the absence of fibrin, has greater resistance to cleavage by plasmin than native t-PA, and has increased plasma half-life as compared to native t-PA. These homologs are also characterized as having at least one amino acid substitution within four amino acid residues of the activa­tion site corresponding to native t-PA. The DNA constructs, expression vectors, and pharmaceutical compositions relating to these t-PA homologs are also disclosed.

    摘要翻译： 公开了在纤维蛋白存在下具有天然t-PA的纤维蛋白溶解能力的组织型纤溶酶原激活物（t-PA）同系物。 这些同源物基本上由氨基末端纤维蛋白结合结构域和羧基末端丝氨酸蛋白酶结构域组成，其中所述同源物在不存在纤维蛋白的情况下基本上是纤维蛋白结合的无活性的，比天然t-PA具有更强的抗纤溶酶切割抗性， 并且与天然t-PA相比具有增加的血浆半衰期。 这些同系物的特征还在于对应于天然t-PA的激活位点的四个氨基酸残基内具有至少一个氨基酸取代。 还公开了与这些t-PA同系物相关的DNA构建体，表达载体和药物组合物。